Literature DB >> 10655057

Aberrant CpG-island methylation has non-random and tumour-type-specific patterns.

J F Costello1, M C Frühwald, D J Smiraglia, L J Rush, G P Robertson, X Gao, F A Wright, J D Feramisco, P Peltomäki, J C Lang, D E Schuller, L Yu, C D Bloomfield, M A Caligiuri, A Yates, R Nishikawa, H Su Huang, N J Petrelli, X Zhang, M S O'Dorisio, W A Held, W K Cavenee, C Plass.   

Abstract

CpG islands frequently contain gene promoters or exons and are usually unmethylated in normal cells. Methylation of CpG islands is associated with delayed replication, condensed chromatin and inhibition of transcription initiation. The investigation of aberrant CpG-island methylation in human cancer has primarily taken a candidate gene approach, and has focused on less than 15 of the estimated 45,000 CpG islands in the genome. Here we report a global analysis of the methylation status of 1,184 unselected CpG islands in each of 98 primary human tumours using restriction landmark genomic scanning (RLGS). We estimate that an average of 600 CpG islands (range of 0 to 4,500) of the 45,000 in the genome were aberrantly methylated in the tumours, including early stage tumours. We identified patterns of CpG-island methylation that were shared within each tumour type, together with patterns and targets that displayed distinct tumour-type specificity. The expression of many of these genes was reactivated by experimental demethylation in cultured tumour cells. Thus, the methylation of particular subsets of CpG islands may have consequences for specific tumour types.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655057     DOI: 10.1038/72785

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  372 in total

1.  Regulation of DNA methylation of Rasgrf1.

Authors:  Bong June Yoon; Herry Herman; Aimee Sikora; Laura T Smith; Christoph Plass; Paul D Soloway
Journal:  Nat Genet       Date:  2001-12-20       Impact factor: 38.330

2.  Identification and characterization of the potential promoter regions of 1031 kinds of human genes.

Authors:  Y Suzuki; T Tsunoda; J Sese; H Taira; J Mizushima-Sugano; H Hata; T Ota; T Isogai; T Tanaka; Y Nakamura; A Suyama; Y Sakaki; S Morishita; K Okubo; S Sugano
Journal:  Genome Res       Date:  2001-05       Impact factor: 9.043

3.  Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry.

Authors:  Jörg Tost; Philipp Schatz; Matthias Schuster; Kurt Berlin; Ivo Glynne Gut
Journal:  Nucleic Acids Res       Date:  2003-05-01       Impact factor: 16.971

Review 4.  Identification of driver and passenger DNA methylation in cancer by epigenomic analysis.

Authors:  Satish Kalari; Gerd P Pfeifer
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

5.  DNA methylation biomarkers for lung cancer.

Authors:  Tibor A Rauch; Zunde Wang; Xiwei Wu; Kemp H Kernstine; Arthur D Riggs; Gerd P Pfeifer
Journal:  Tumour Biol       Date:  2011-12-06

6.  Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis.

Authors:  R C Sobti; Neha Singh; Showket Hussain; Vanita Suri; Raje Nijhawan; A C Bharti; Mausumi Bharadwaj; B C Das
Journal:  Cell Oncol (Dordr)       Date:  2011-09-21       Impact factor: 6.730

7.  Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma.

Authors:  Jun-Xiong Wang; Yuan-Long He; Sheng-Tao Zhu; Shuo Yang; Shu-Tian Zhang
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

8.  Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.

Authors:  Guillermo Garcia-Manero; Elizabeth A Griffiths; David P Steensma; Gail J Roboz; Richard Wells; James McCloskey; Olatoyosi Odenike; Amy E DeZern; Karen Yee; Lambert Busque; Casey O'Connell; Laura C Michaelis; Joseph Brandwein; Hagop Kantarjian; Aram Oganesian; Mohammad Azab; Michael R Savona
Journal:  Blood       Date:  2020-08-06       Impact factor: 22.113

9.  Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth.

Authors:  Chibo Hong; K Scott Moorefield; Peter Jun; Kenneth D Aldape; Samir Kharbanda; Heidi S Phillips; Joseph F Costello
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

Review 10.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.